Publications

PIM1 related publications:
  1. Small J, Washburn E, Millington K, Zhu J, Holder SL.  The Addition of Abemaciclib to Sunitinib Induces Regression of Renal Cell Carcinoma Xenograft Tumors. Oncotarget. 2017; 8:95116-95134. https://doi.org/10.18632/oncotarget.19618.
  2. Holder SL, Abdulkadir SA. PIM1 Kinase as a Target in Prostate Cancer: Roles in Tumorigenesis, Castration Resistance, and Docetaxel Resistance. Curr Cancer Drug Targets. 2013 Nov 25. [Epub ahead of print]
  3. Holder S, Lilly M, Brown ML.  Comparative Molecular Field Analysis of Flavonoid Inhibitors of the PIM-1 Kinase.  Bioorg Med Chem.  2007 Oct 1;15(19):6463-73.
  4. Holder S, Zemskova M, Kumar A, Zhang C, Tabrizizad M, Bremer R, Neidigh J, Lilly MB.  Characterization of a Potent and Selective Small-Molecule Inhibitor of the PIM1 Kinase.  Mol Cancer Ther. 2007 Jan;6(1) 163-172. Cover article.

 

Select Recent Publications:
  1. Joshi M, Holder SL, Zhu J, Zheng H, Komanduri S, Warrick J, Yasin H, Garje R, Jia B, Drabick JJ, DeGraff DJ, Zakharia Y. Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study. Eur Urol Focus. 2021 Mar 17;. doi: 10.1016/j.euf.2021.03.005. [Epub ahead of print] PubMed PMID: 33741296.
  2. Yin M, Grivas P, Wang QE, Mortazavi A, Emamekhoo H, Holder SL, Drabick JJ, Woo MS, Pal S, Vasekar M, Folefac E, Clinton SK, Monk P, Joshi M. Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer. Oncologist. 2020 Aug;25(8):680-688. doi: 10.1634/theoncologist.2019-0851. Epub 2020 May 13. PubMed PMID: 32275806; PubMed Central PMCID: PMC7418353.
  3. Wang M, Chi G, Bodovski Y, Holder SL, Lengerich EJ, Wasserman E, McDonald AC. Temporal and spatial trends and determinants of aggressive prostate cancer among Black and White men with prostate cancer. Cancer Causes Control. 2020 Jan;31(1):63-71. doi: 10.1007/s10552-019-01249-0. Epub 2019 Nov 15. PubMed PMID: 31732913.

For a complete list of publications click here.